Targeting RARγ to treat disease is a promising prospect because for prostate cancer, agonism of RARγ stimulated the growth of and colony formation by prostate cancer cell line cells and antagonising led to necroptosis of the cell line colony forming CSC-like cells and patients’ cells (Petrie et al., 2022). The gene discussed is RARG; the disease is prostate carcinoma.